Please login to the form below

Not currently logged in
Email:
Password:

Severe immune deficiency trial approved

A clinical trial of a gene therapy for the rare immunodeficiency, Wiskott-Aldrich syndrome, has been approved in France and the UK

A clinical trial of a gene therapy for the rare immunodeficiency, Wiskott-Aldrich syndrome (WAS), has been approved in France and the UK. It will be sponsored by Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM), with funding from France's annual Telethon. 

The French and British health authorities have authorised the phase I/II trial, which will be conducted both at Necker Children's Hospital, Paris, and at London's Great Ormond Street Hospital.   

WAS is a severe, X-linked immunodeficiency which results in haemorrhage, recurrent infection and eczema. It is almost always fatal in affected children. Although a bone marrow transplant can re-establish the patient's immune system, this requires a compatible donor and carries a risk of failure. Gene therapy is a major source of hope, therefore.   

This trial is the result of research initiated in 2002 in the Généthon laboratory. The researchers have developed an ex-vivo approach that uses an HIV-derived lentiviral vector to transfer genes into autologous CD34+ haematopoietic stem cells from the patient.  

"This trial is enabling the Généthon laboratory to demonstrate its world-class expertise in the production of gene-based medicines and the preparation and implementation of clinical trials." stated AFM and Généthon president, Laurence Tiennot-Herment. "It confirms Généthon's ability to become a major international player in demonstrating the efficacy of gene therapy for rare diseases."  

Généthon is a leading centre for preclinical and clinical research and development in the field of gene therapy. It has a biomanufacturing platform for clinical-grade vectors and is involved in building the world's largest facility for pre-industrial pilot production at Evry, France, that is scheduled to open in early 2011.     

24th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics